GT Healthcare Capital Partners

Autobahn Therapeutics develops brain-targeting, small molecule therapies for central nervous system disorders. Its lead program ABX-002 is a thyroid hormone receptor beta agonist being developed as an adjunctive treatment for mood disorders, including major depressive disorder and bipolar depression. The company emphasizes precision tuning of CNS exposure, validated clinical and biologic targets, and biomarker-guided development across neuropsychiatry, neurodegeneration, and neuroinflammation to address high unmet medical needs and improve patient outcomes.

Moon Surgical is a medical device company focused on enhancing minimally invasive surgical procedures through advanced robotics. The company is developing the Maestro System, a surgical robot designed to assist in laparoscopy by improving access to these techniques and optimizing the use of resources in the operating room. This technology provides surgeons with enhanced control and adaptability to various surgical conditions, thereby increasing efficiency and improving patient care. Moon Surgical's devices facilitate the stabilization and automatic positioning of endoscopes, as well as organ retraction, while maintaining the traditional surgical workflow. Through its innovative approach, Moon Surgical aims to transform surgical practices and enhance the overall surgical experience for both surgeons and patients.

Autobahn Therapeutics develops brain-targeting, small molecule therapies for central nervous system disorders. Its lead program ABX-002 is a thyroid hormone receptor beta agonist being developed as an adjunctive treatment for mood disorders, including major depressive disorder and bipolar depression. The company emphasizes precision tuning of CNS exposure, validated clinical and biologic targets, and biomarker-guided development across neuropsychiatry, neurodegeneration, and neuroinflammation to address high unmet medical needs and improve patient outcomes.

Moon Surgical is a medical device company focused on enhancing minimally invasive surgical procedures through advanced robotics. The company is developing the Maestro System, a surgical robot designed to assist in laparoscopy by improving access to these techniques and optimizing the use of resources in the operating room. This technology provides surgeons with enhanced control and adaptability to various surgical conditions, thereby increasing efficiency and improving patient care. Moon Surgical's devices facilitate the stabilization and automatic positioning of endoscopes, as well as organ retraction, while maintaining the traditional surgical workflow. Through its innovative approach, Moon Surgical aims to transform surgical practices and enhance the overall surgical experience for both surgeons and patients.

Boundless Bio, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, focused on developing innovative therapies for the treatment of aggressive cancers. The company specializes in targeting extrachromosomal DNA (ecDNA), a key factor in the amplification of oncogenes that affects over 14% of cancer patients. By investigating the biology of ecDNA, Boundless Bio aims to create transformative treatments for previously untreatable cancers. Its lead therapeutic candidate, BBI-355, is an oral selective inhibitor of checkpoint kinase 1 (CHK1) designed to manage the replication and transcription of ecDNA in cancer cells. Founded in 2018, Boundless Bio is committed to addressing the significant unmet medical needs of patients with oncogene amplified tumors.

Exscientia is a biotechnology company that leverages artificial intelligence and machine learning to enhance the discovery and design of novel therapeutic compounds. By integrating human expertise with advanced computational techniques, Exscientia accelerates the development of small-molecule drug candidates, aiming to produce safe and effective treatments for clinical testing. The company's innovative approach seeks to revolutionize the pharmaceutical industry by improving the precision and efficiency of drug discovery, ultimately enhancing patient outcomes.

Exscientia is a biotechnology company that leverages artificial intelligence and machine learning to enhance the discovery and design of novel therapeutic compounds. By integrating human expertise with advanced computational techniques, Exscientia accelerates the development of small-molecule drug candidates, aiming to produce safe and effective treatments for clinical testing. The company's innovative approach seeks to revolutionize the pharmaceutical industry by improving the precision and efficiency of drug discovery, ultimately enhancing patient outcomes.

G.I. Windows, Inc. is a clinical-stage company based in West Bridgewater, Massachusetts, founded in 2012. The company specializes in manufacturing medical devices utilizing advanced surgical anastomotic technology aimed at treating obesity and type 2 diabetes. G.I. Windows is focused on developing innovative solutions that enable less invasive surgical procedures, thereby creating a new category in healthcare. Its technology is designed to enhance the efficiency of diagnostic and interventional procedures, ultimately improving patient outcomes while reducing overall healthcare costs.

Exscientia is a biotechnology company that leverages artificial intelligence and machine learning to enhance the discovery and design of novel therapeutic compounds. By integrating human expertise with advanced computational techniques, Exscientia accelerates the development of small-molecule drug candidates, aiming to produce safe and effective treatments for clinical testing. The company's innovative approach seeks to revolutionize the pharmaceutical industry by improving the precision and efficiency of drug discovery, ultimately enhancing patient outcomes.

Oxford VR Limited is a company that specializes in developing cognitive treatments for clinical conditions utilizing virtual reality technology. Founded in 2016 and based in Oxford, United Kingdom, it emerged as a spin-out from Oxford University, building on the research of Professor Daniel Freeman. The company offers automated treatments delivered by a virtual coach, targeting conditions such as fear of heights, psychosis, and social anxiety. By leveraging immersive virtual reality, Oxford VR aims to provide faster and more effective therapies at a lower cost to health providers. The treatments are designed to be user-centered and clinically validated, thereby enhancing access to mental health care while significantly impacting patients and the broader healthcare system.

Zap Surgical Systems, based in San Carlos, California, specializes in developing advanced medical technologies. Founded in 2014, the company's flagship product is ZAP-X, a gyroscopic radiosurgery platform designed for precise, non-invasive treatment of brain tumors and head & neck conditions. Unlike traditional systems, ZAP-X's self-shielded design eliminates the need for radiation vaults, enabling its use in various healthcare settings previously unfeasible or cost-prohibitive.

G.I. Windows, Inc. is a clinical-stage company based in West Bridgewater, Massachusetts, founded in 2012. The company specializes in manufacturing medical devices utilizing advanced surgical anastomotic technology aimed at treating obesity and type 2 diabetes. G.I. Windows is focused on developing innovative solutions that enable less invasive surgical procedures, thereby creating a new category in healthcare. Its technology is designed to enhance the efficiency of diagnostic and interventional procedures, ultimately improving patient outcomes while reducing overall healthcare costs.

Boundless Bio, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, focused on developing innovative therapies for the treatment of aggressive cancers. The company specializes in targeting extrachromosomal DNA (ecDNA), a key factor in the amplification of oncogenes that affects over 14% of cancer patients. By investigating the biology of ecDNA, Boundless Bio aims to create transformative treatments for previously untreatable cancers. Its lead therapeutic candidate, BBI-355, is an oral selective inhibitor of checkpoint kinase 1 (CHK1) designed to manage the replication and transcription of ecDNA in cancer cells. Founded in 2018, Boundless Bio is committed to addressing the significant unmet medical needs of patients with oncogene amplified tumors.

GT Apeiron Therapeutics is a developer of innovative drugs utilizing artificial intelligence technology. The company develops breakthrough investigational medicines by harnessing the power of artificial intelligence, aiming to drastically increase efficiency throughout the drug discovery process.

Exscientia is a biotechnology company that leverages artificial intelligence and machine learning to enhance the discovery and design of novel therapeutic compounds. By integrating human expertise with advanced computational techniques, Exscientia accelerates the development of small-molecule drug candidates, aiming to produce safe and effective treatments for clinical testing. The company's innovative approach seeks to revolutionize the pharmaceutical industry by improving the precision and efficiency of drug discovery, ultimately enhancing patient outcomes.

Oxford VR Limited is a company that specializes in developing cognitive treatments for clinical conditions utilizing virtual reality technology. Founded in 2016 and based in Oxford, United Kingdom, it emerged as a spin-out from Oxford University, building on the research of Professor Daniel Freeman. The company offers automated treatments delivered by a virtual coach, targeting conditions such as fear of heights, psychosis, and social anxiety. By leveraging immersive virtual reality, Oxford VR aims to provide faster and more effective therapies at a lower cost to health providers. The treatments are designed to be user-centered and clinically validated, thereby enhancing access to mental health care while significantly impacting patients and the broader healthcare system.

ONI is a pioneering company in super-resolution microscopy, dedicated to making advanced imaging technology accessible to researchers. Its flagship product, the Nanoimager, is the first benchtop-sized super-resolution microscope, significantly enhancing usability and precision in biological research. This innovative device allows users to access various super-resolution techniques, including dSTORM, PALM, smFRET, and single-particle tracking, facilitating a deeper understanding of cellular structures and functions. ONI's products are increasingly adopted by leading laboratories worldwide, including institutions such as the Universities of Oxford, Cambridge, and Harvard. The company's mission is to democratize super-resolution fluorescence imaging, thereby accelerating scientific discovery and aiding in disease research by enabling researchers to visualize and comprehend the intricate details of life at the molecular level. Recognized for its contributions to the field, ONI has received accolades for its innovative approach and commitment to enhancing the effectiveness and accessibility of scientific research.

Potrero Medical, Inc. is a predictive health company that specializes in developing advanced monitoring devices to detect subtle changes in physiological parameters. The company's products are designed to provide early warnings of conditions such as sepsis and systemic inflammatory response syndrome, while also optimizing treatment by detecting and preventing fluid overload during resuscitation efforts. Potrero Medical's devices monitor various metrics, including intra-abdominal pressure, core body temperature, heart rate, respiratory rate, relative cardiac output, and urine output. Founded in 2011 and based in San Francisco, California, the company aims to leverage smart sensors and artificial intelligence to enhance the ability of medical teams to predict adverse outcomes in critical care environments.

Ultromics Limited, founded in 2017 and based in Oxford, United Kingdom, specializes in developing advanced echocardiography software aimed at enhancing the diagnosis of coronary heart disease. By leveraging artificial intelligence, the company has created highly accurate diagnostic tools that improve the identification of coronary artery disease, achieving diagnostic accuracy improvements of over 90%. Ultromics' technology processes complex data from electrocardiograms, empowering healthcare providers to make informed clinical decisions and ultimately enhancing patient care in cardiology.

RefleXion Medical Inc. is a medical equipment company based in Hayward, California, focused on revolutionizing cancer treatment through its biologically-guided radiotherapy system (BgRT). This innovative technology allows tumors to continuously signal their location during treatment, enabling the simultaneous targeting of multiple tumors, even in cases of metastasized cancer. The RefleXion X1 machine is cleared for various forms of radiotherapy, including stereotactic body radiotherapy, stereotactic radiosurgery, and intensity-modulated radiotherapy. The BgRT system utilizes positron-emission tomography (PET) imaging data to synchronize tumor location information with the linear accelerator, allowing for real-time adjustments in treatment delivery with subsecond latency. RefleXion Medical has established strategic collaborations with Telix Pharmaceuticals Limited and HealthMyne Inc. since its incorporation in 2009.

ONI is a pioneering company in super-resolution microscopy, dedicated to making advanced imaging technology accessible to researchers. Its flagship product, the Nanoimager, is the first benchtop-sized super-resolution microscope, significantly enhancing usability and precision in biological research. This innovative device allows users to access various super-resolution techniques, including dSTORM, PALM, smFRET, and single-particle tracking, facilitating a deeper understanding of cellular structures and functions. ONI's products are increasingly adopted by leading laboratories worldwide, including institutions such as the Universities of Oxford, Cambridge, and Harvard. The company's mission is to democratize super-resolution fluorescence imaging, thereby accelerating scientific discovery and aiding in disease research by enabling researchers to visualize and comprehend the intricate details of life at the molecular level. Recognized for its contributions to the field, ONI has received accolades for its innovative approach and commitment to enhancing the effectiveness and accessibility of scientific research.

Oxford Nanopore Technologies Limited is a biotechnology company specializing in the development and commercialization of nanopore-based sequencing technology for the analysis of DNA, RNA, proteins, and small molecules. Its innovative product lineup includes the portable MinION device, the benchtop PromethION, and the GridION system, all of which enable real-time data streaming and scalable sequencing for a variety of applications in scientific research, personalized medicine, environmental monitoring, and agriculture. The Flongle offers smaller, on-demand sequencing solutions, catering to users requiring rapid insights. Operating in over 80 countries, Oxford Nanopore's technology is designed for accessibility and ease of use, featuring straightforward library preparation and automated solutions. The company maintains a robust patent portfolio, supporting its ongoing research and development in both biological and solid-state nanopore technologies. Founded in 2005 and based in Oxford, United Kingdom, Oxford Nanopore Technologies also has offices in multiple countries, including the United States, China, and Germany.